Novo Nordisk released full results from a late-stage trial showing that its Wegovy injection helped children ages 6 to under 12 with obesity lower their body mass index (BMI), according to the company.

Novo said Wegovy reduced BMI by an estimated 19.7 percentage points on average compared with a placebo at 68 weeks. BMI fell 17.4% among children receiving the drug and rose 2.2% among those receiving a placebo. These results assumed patients stayed on treatment. Across all children in the study, including those who stopped treatment, Wegovy lowered BMI by an estimated 16.2 percentage points more than the placebo. All 167 children also received lifestyle changes, including a reduced-calorie diet and more physical activity.

Novo said Wegovy's safety and tolerability in children were consistent with those seen in adult trials. The company reported no safety concerns related to growth or pubertal development.

Dr. Andrea Traina, Novo's medical director lead of obesity, said 85% of the children started with moderate to severe obesity and nearly half had at least one obesity-related complication, such as high blood pressure, high cholesterol or sleep apnea. She said more than 40% of treated children were no longer classified as having obesity after 68 weeks, assuming they stayed on treatment. Novo first shared that result in September.

Wegovy is already approved for obesity in children 12 and older. The report says no approved medications currently exist for children under 12. Traina said the two-year study does not show whether earlier treatment changes the long-term course of the disease, or what treatment and maintenance would look like as children become adults. She described this as an evidence gap that future research could address.